Valmet will support Faderco Group doubling tissue production capacity with a third Advantage DCT tissue line

Valmet has received an order from WARAK (a Faderco Group subsidiary) for a complete Advantage DCT 200TS tissue production line, including stock preparation, automation (Valmet DNA), two Focus rewinders and full engineering, installation and commissioning; start-up is scheduled for Q1 2027. The third Valmet-supplied line for Faderco will double the group's tissue capacity—adding 65,000 tonnes/year—and targets domestic and export markets across Southern Europe, the UK and Africa while emphasizing lower energy and water use. The order is recorded in Valmet’s Q4 2025 orders received; the contract value was not disclosed. For investors, the news is a positive operational win for Valmet with modest near-term market impact given the undisclosed value and multi-year delivery timetable.

Analysis

Market structure: Faderco’s +65,000 tpa tissue line (startup Q1 2027) strengthens North African capacity and export supply into Southern Europe/UK, likely depressing regional spot tissue prices by low-single-digits and raising competitive pressure on smaller local producers. Valmet (VALMT.HE) is a direct winner — order supports aftermarket, automation and installation revenues; given Valmet’s EUR 5.4bn 2024 sales, this single order is likely <1–2% of annual revenue but meaningful for niche margins and recurring services.

Risk assessment: Tail risks include construction/start-up delays, Algerian export regulation or FX/capital controls, and potential machine performance/warranty disputes; any of these could push commissioning beyond 2027 or incur >€10–30m remediation. Short-term (days–months) market reaction will be muted; medium-term (6–18 months) risks center on orderbook recognition and supply-chain bottlenecks (spare parts, skilled operators); long-term (2–5 years) outcome depends on Faderco converting capacity into profitable exports.

Trade implications: Primary trade is a modest long in Valmet (equipment + services exposure) with an options overlay to cap downside; secondary plays include selective longs in automation/industrial equipment suppliers and underweight positions in regional small-cap tissue manufacturers whose local pricing could compress. Cross-asset: minor upward pressure on pulp/recycled fiber demand (order implies incremental pulp demand in the tens of ktpa), negligible sovereign bond or FX impact unless Algeria policy shifts.

Contrarian angles: Consensus may underweight recurring service/automation upside — aftermarket could add 3–5% to Valmet’s margins over 3 years if similar orders scale. Conversely, the market could be underestimating regional oversupply risk: if several peers replicate expansion, tissue pricing could fall >5–10% in Southern Europe, hurting producers’ EBITDA margins and making equipment OEM equities mean-reverting.

Key Decisions for Investors

• Establish a 1–2% long position in Valmet (VALMT.HE) within 30 days to capture backlog and aftermarket upside; target +20% total return over 12 months, set stop-loss at -8% absolute to limit execution/warranty risk.
• Implement a funded options bull-call spread on VALMT: buy 12-month ATM calls and sell 12-month calls 20% OTM sized to equal 1% portfolio risk — reduces premium outlay while expressing asymmetric upside to Q1 2027 startup and services ramp.
• Pair trade: go long VALMT (1%) and short International Paper (IP, 0.5%) over 6–12 months — thesis: Valmet benefits from capex/automation demand, IP faces commodity/pulp cyclicality and regional pricing pressure; expect VALMT to outperform IP by ~10% in 12 months.
• Avoid new direct exposure to small/medium European tissue producers; if regional tissue spot prices drop >5% over any 3‑month window, initiate 0.5–1% short positions in publicly listed niche tissue players or increase put protection on existing holdings.
• Monitor three catalysts and act within set windows: Valmet order intake/earnings (next 60 days) — +10% QoQ tissue order intake => add 0.5% to VALMT long; watch Algerian export/regulatory announcements (next 180 days) — any export restriction => trim VALMT exposure by 50%.